Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Short Interest Update

by · The Markets Daily

Fidelity Disruptive Medicine ETF (NASDAQ:FMED – Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 2,571 shares, an increase of 65.0% from the December 31st total of 1,558 shares. Based on an average trading volume of 10,271 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the company’s shares are short sold. Currently, 0.1% of the company’s shares are short sold. Based on an average trading volume of 10,271 shares, the short-interest ratio is presently 0.3 days.

Fidelity Disruptive Medicine ETF Stock Performance

FMED stock traded down $0.31 during mid-day trading on Friday, reaching $26.67. 3,796 shares of the stock traded hands, compared to its average volume of 8,795. Fidelity Disruptive Medicine ETF has a one year low of $20.69 and a one year high of $29.07. The stock has a market capitalization of $61.34 million, a PE ratio of 41.33 and a beta of 1.00. The business has a 50-day moving average price of $27.69 and a two-hundred day moving average price of $25.97.

Institutional Trading of Fidelity Disruptive Medicine ETF

Several institutional investors and hedge funds have recently modified their holdings of the stock. Glass Jacobson Investment Advisors llc grew its stake in Fidelity Disruptive Medicine ETF by 44.0% in the fourth quarter. Glass Jacobson Investment Advisors llc now owns 1,260 shares of the company’s stock worth $34,000 after purchasing an additional 385 shares in the last quarter. BXM Wealth LLC bought a new position in shares of Fidelity Disruptive Medicine ETF during the 4th quarter worth $243,000. Jane Street Group LLC grew its position in shares of Fidelity Disruptive Medicine ETF by 0.8% during the 1st quarter. Jane Street Group LLC now owns 66,382 shares of the company’s stock worth $1,567,000 after buying an additional 499 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its stake in shares of Fidelity Disruptive Medicine ETF by 4.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 714,991 shares of the company’s stock valued at $19,712,000 after buying an additional 31,629 shares during the period.

About Fidelity Disruptive Medicine ETF

(Get Free Report)

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.

Read More